Chinook Therapeutics (NASDAQ:KDNY) announced its earnings results on Tuesday. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.82), MarketWatch Earnings reports. Chinook Therapeutics had a negative return on equity of 112.72% and a negative net margin of 215.80%.
KDNY stock opened at $14.75 on Thursday. The stock’s fifty day moving average is $16.88. Chinook Therapeutics has a one year low of $10.50 and a one year high of $21.68. The company has a market capitalization of $621.83 million, a PE ratio of -4.10 and a beta of 0.26.
A number of research firms have recently issued reports on KDNY. Bloom Burton reiterated a “buy” rating on shares of Chinook Therapeutics in a report on Monday, March 22nd. Wedbush began coverage on shares of Chinook Therapeutics in a report on Wednesday, January 6th. They issued an “outperform” rating and a $28.00 price objective on the stock. Zacks Investment Research upgraded shares of Chinook Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, January 11th. Finally, Cantor Fitzgerald assumed coverage on shares of Chinook Therapeutics in a report on Wednesday, December 9th. They issued an “overweight” rating and a $31.00 price objective on the stock. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $28.29.
Chinook Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, an investigational Phase III ready endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases.
See Also: CBOE Russell 2000® Volatility Index
Receive News & Ratings for Chinook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chinook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.